Preventing Relapse in Schizophrenia: Oral Antipsychotics Compared To Injectables: Evaluating Efficacy (PROACTIVE)

This study is currently recruiting participants.
Information provided by National Institute of Mental Health (NIMH)

Find Related Studies by Searching for the Conditions, Interventions, and Sponsors found in this study:

1		Conditions listed in this trial
			Schizophrenia
			Schizoaffective Disorder
2		Additional conditions recognized in this trial
			Psychotic Disorders
			Recurrence
3		More general conditions related to this trial
			Disease Attributes
			Mental Disorders
			Pathologic Processes
			Schizophrenia and Disorders with Psychotic Features
4		Interventions listed in this trial
			Risperidone microspheres
			Risperidone
			Olanzapine
			Quetiapine
			Ziprasidone
			Aripiprazole
			Paliperidone
5		Additional drug interventions recognized in this trial
			9-hydroxy-risperidone
6		More general drug interventions related to this trial
			Antiemetics
			Antipsychotic Agents
			Autonomic Agents
			Central Nervous System Agents
			Central Nervous System Depressants
			Dopamine Agents
			Dopamine Antagonists
			Gastrointestinal Agents
			Molecular Mechanisms of Pharmacological Action
			Neurotransmitter Agents
			Neurotransmitter Uptake Inhibitors
			Peripheral Nervous System Agents
			Pharmacologic Actions
			Physiological Effects of Drugs
			Psychotropic Drugs
			Serotonin Agents
			Serotonin Antagonists
			Serotonin Uptake Inhibitors
			Therapeutic Uses
			Tranquilizing Agents
7		Sponsors listed in this trial
			National Institute of Mental Health (NIMH)